CN1035179C - 新的吲哚衍生物 - Google Patents
新的吲哚衍生物 Download PDFInfo
- Publication number
- CN1035179C CN1035179C CN93109364A CN93109364A CN1035179C CN 1035179 C CN1035179 C CN 1035179C CN 93109364 A CN93109364 A CN 93109364A CN 93109364 A CN93109364 A CN 93109364A CN 1035179 C CN1035179 C CN 1035179C
- Authority
- CN
- China
- Prior art keywords
- formula
- alkyl
- branched
- straight
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 238000006114 decarboxylation reaction Methods 0.000 claims abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 229940054051 antipsychotic indole derivative Drugs 0.000 claims description 8
- 150000002475 indoles Chemical class 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- -1 methoxyl group Chemical group 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- JJWOMLRJNXMLSO-UHFFFAOYSA-N 1-methylsulfonylpiperidine Chemical class CS(=O)(=O)N1CCCCC1 JJWOMLRJNXMLSO-UHFFFAOYSA-N 0.000 claims 1
- QSDFYHFWELYRMZ-UHFFFAOYSA-N ethyl 4-methylsulfonylpiperazine-1-carboxylate Chemical compound CCOC(=O)N1CCN(S(C)(=O)=O)CC1 QSDFYHFWELYRMZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 abstract description 4
- 206010027599 migraine Diseases 0.000 abstract description 4
- HCUARRIEZVDMPT-UHFFFAOYSA-N indolyl-2-carboxylic acid Natural products C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 abstract 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 239000000370 acceptor Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 241000009328 Perro Species 0.000 description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229960005137 succinic acid Drugs 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 3
- 229960003708 sumatriptan Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010047139 Vasoconstriction Diseases 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000002460 anti-migrenic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229960004643 cupric oxide Drugs 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 230000025033 vasoconstriction Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 101710138068 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
- 102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- FCLZCOCSZQNREK-UHFFFAOYSA-N Pyrrolidine, hydrochloride Chemical compound Cl.C1CCNC1 FCLZCOCSZQNREK-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101000783611 Takifugu rubripes 5-hydroxytryptamine receptor 1D Proteins 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002012 dioxanes Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 201000003152 motion sickness Diseases 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Processing Of Solid Wastes (AREA)
- Fertilizers (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929216009A GB9216009D0 (en) | 1992-07-28 | 1992-07-28 | New indol derivatives |
| GB9216009.2 | 1992-07-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1087629A CN1087629A (zh) | 1994-06-08 |
| CN1035179C true CN1035179C (zh) | 1997-06-18 |
Family
ID=10719423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN93109364A Expired - Lifetime CN1035179C (zh) | 1992-07-28 | 1993-07-28 | 新的吲哚衍生物 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US5565447A (enExample) |
| EP (1) | EP0605697B1 (enExample) |
| JP (1) | JP2716585B2 (enExample) |
| KR (1) | KR100191830B1 (enExample) |
| CN (1) | CN1035179C (enExample) |
| AT (1) | ATE177080T1 (enExample) |
| BR (2) | BR9305589A (enExample) |
| CA (1) | CA2120028C (enExample) |
| CZ (1) | CZ282659B6 (enExample) |
| DE (2) | DE10199016I2 (enExample) |
| DK (1) | DK0605697T3 (enExample) |
| EC (1) | ECSP930953A (enExample) |
| EG (1) | EG20340A (enExample) |
| FI (1) | FI109998B (enExample) |
| GB (1) | GB9216009D0 (enExample) |
| GR (1) | GR3029915T3 (enExample) |
| HU (2) | HUT70518A (enExample) |
| IL (1) | IL106387A (enExample) |
| LU (1) | LU90758I2 (enExample) |
| MX (1) | MX9304524A (enExample) |
| MY (1) | MY113266A (enExample) |
| NL (1) | NL300053I2 (enExample) |
| NO (1) | NO180231C (enExample) |
| NZ (1) | NZ254152A (enExample) |
| PL (1) | PL174352B1 (enExample) |
| RU (1) | RU2117667C1 (enExample) |
| SG (1) | SG48708A1 (enExample) |
| TW (1) | TW235297B (enExample) |
| UA (1) | UA27818C2 (enExample) |
| UY (1) | UY23624A1 (enExample) |
| WO (1) | WO1994002460A1 (enExample) |
| ZA (1) | ZA935316B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2712591B1 (fr) * | 1993-11-19 | 1996-02-09 | Pf Medicament | Nouvelles arylpipérazines dérivées d'indole, leur préparation et leur utilisation thérapeutique. |
| FR2731224B1 (fr) * | 1995-03-02 | 1997-05-30 | Pf Medicament | Nouveaux derives bi-tryptaminiques sulfonamides, leur procede de preparation et leur utilisation a titre de medicaments |
| GB9523462D0 (en) * | 1995-11-16 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| US8022095B2 (en) | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US7189753B1 (en) | 1997-11-06 | 2007-03-13 | Cady Roger K | Preemptive prophylaxis of migraine |
| US6204274B1 (en) | 1998-04-29 | 2001-03-20 | American Home Products Corporation | Indolyl derivatives as serotonergic agents |
| US6310066B1 (en) | 1998-04-29 | 2001-10-30 | American Home Products Corp. | Antipsychotic indolyl derivatives |
| US6066637A (en) * | 1998-06-19 | 2000-05-23 | American Home Products Corporation | Indolyl derivatives as serotonergic agents |
| US20060004029A1 (en) * | 2002-08-30 | 2006-01-05 | Akihiko Tsuruoka | Nitrogen-containing aromatic derivatives |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| JP4878285B2 (ja) * | 2003-06-05 | 2012-02-15 | エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング | アポトーシス誘発作用を有するインドール誘導体 |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| DE602005020280D1 (de) * | 2004-06-01 | 2010-05-12 | Hoffmann La Roche | 3-amino-1-arylpropyl-indole als monoamin-wiederaufnahmehemmer |
| WO2006129190A1 (en) * | 2005-06-03 | 2006-12-07 | Glenmark Pharmaceuticals Limited | Process for the preparation of almotriptan |
| US20070112055A1 (en) * | 2005-09-30 | 2007-05-17 | Glenmark Pharmaceuticals Limited | Crystalline forms of almotriptan and processes for their preparation |
| DE102006027229A1 (de) * | 2006-06-09 | 2007-12-20 | Grünenthal GmbH | 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
| WO2008049116A2 (en) | 2006-10-19 | 2008-04-24 | Auspex Pharmaceuticals, Inc. | Substituted indoles |
| TWI321616B (en) | 2007-03-27 | 2010-03-11 | Coretronic Corp | Centrifugal blower |
| CZ302424B6 (cs) * | 2007-06-13 | 2011-05-11 | Zentiva, A. S. | Zpusob prípravy almotriptanu o vysoké cistote |
| US20100292290A1 (en) * | 2007-08-02 | 2010-11-18 | Vinayak Gore | Novel process to prepare almotriptan |
| CN103724252A (zh) * | 2012-10-12 | 2014-04-16 | 苏州四同医药科技有限公司 | 一种阿莫曲坦的制备方法 |
| EP3766483A1 (en) | 2019-07-19 | 2021-01-20 | BioPharma Synergies, S. L. | Orodispersible powder composition comprising a triptan |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2082175A (en) * | 1980-08-12 | 1982-03-03 | Glaxo Group Ltd | Heterocyclic compounds |
| GB2124210A (en) * | 1982-06-07 | 1984-02-15 | Glaxo Group Ltd | Indoles |
| GB2168347A (en) * | 1984-12-13 | 1986-06-18 | Glaxo Group Ltd | Indoles |
| EP0303506A2 (en) * | 1987-08-13 | 1989-02-15 | Glaxo Group Limited | Indole derivatives |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2162532B (en) * | 1984-08-04 | 1988-08-03 | Ritchie Swanson John | Decontaminant wash composition |
| CZ288351B6 (en) * | 1990-06-07 | 2001-05-16 | Astrazeneca Ab | Nitrogenous heterocyclic compound, process of its preparation and use as well as a medicament containing thereof |
-
1992
- 1992-07-28 GB GB929216009A patent/GB9216009D0/en active Pending
-
1993
- 1993-07-19 HU HU9400869A patent/HUT70518A/hu unknown
- 1993-07-19 DE DE2001199016 patent/DE10199016I2/de active Active
- 1993-07-19 PL PL93302917A patent/PL174352B1/pl unknown
- 1993-07-19 DE DE69323712T patent/DE69323712T2/de not_active Expired - Lifetime
- 1993-07-19 RU RU94020400A patent/RU2117667C1/ru active
- 1993-07-19 JP JP6504146A patent/JP2716585B2/ja not_active Expired - Lifetime
- 1993-07-19 WO PCT/EP1993/001901 patent/WO1994002460A1/en not_active Ceased
- 1993-07-19 NZ NZ254152A patent/NZ254152A/en not_active IP Right Cessation
- 1993-07-19 DK DK93915953T patent/DK0605697T3/da active
- 1993-07-19 EP EP93915953A patent/EP0605697B1/en not_active Expired - Lifetime
- 1993-07-19 IL IL106387A patent/IL106387A/xx not_active IP Right Cessation
- 1993-07-19 BR BR9305589A patent/BR9305589A/pt not_active Application Discontinuation
- 1993-07-19 SG SG1996000062A patent/SG48708A1/en unknown
- 1993-07-19 KR KR1019940700865A patent/KR100191830B1/ko not_active Expired - Lifetime
- 1993-07-19 AT AT93915953T patent/ATE177080T1/de active
- 1993-07-19 CA CA002120028A patent/CA2120028C/en not_active Expired - Lifetime
- 1993-07-19 CZ CZ94664A patent/CZ282659B6/cs not_active IP Right Cessation
- 1993-07-19 UA UA94005336A patent/UA27818C2/uk unknown
- 1993-07-21 TW TW082105804A patent/TW235297B/zh not_active IP Right Cessation
- 1993-07-22 ZA ZA935316A patent/ZA935316B/xx unknown
- 1993-07-26 EC EC1993000953A patent/ECSP930953A/es unknown
- 1993-07-27 MX MX9304524A patent/MX9304524A/es active IP Right Grant
- 1993-07-28 EG EG47893A patent/EG20340A/xx active
- 1993-07-28 UY UY23624A patent/UY23624A1/es not_active IP Right Cessation
- 1993-07-28 CN CN93109364A patent/CN1035179C/zh not_active Expired - Lifetime
- 1993-07-28 MY MYPI93001483A patent/MY113266A/en unknown
-
1994
- 1994-03-22 NO NO941019A patent/NO180231C/no not_active IP Right Cessation
- 1994-03-25 FI FI941413A patent/FI109998B/fi not_active IP Right Cessation
-
1995
- 1995-05-09 US US08/437,682 patent/US5565447A/en not_active Expired - Lifetime
- 1995-06-30 HU HU95P/P00696P patent/HU211243A9/hu unknown
-
1996
- 1996-10-10 BR BR1100061-9A patent/BR1100061A/pt active IP Right Grant
-
1999
- 1999-04-07 GR GR990401006T patent/GR3029915T3/el unknown
-
2001
- 2001-04-11 LU LU90758C patent/LU90758I2/fr unknown
- 2001-08-21 NL NL300053C patent/NL300053I2/nl unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2082175A (en) * | 1980-08-12 | 1982-03-03 | Glaxo Group Ltd | Heterocyclic compounds |
| GB2124210A (en) * | 1982-06-07 | 1984-02-15 | Glaxo Group Ltd | Indoles |
| GB2168347A (en) * | 1984-12-13 | 1986-06-18 | Glaxo Group Ltd | Indoles |
| EP0303506A2 (en) * | 1987-08-13 | 1989-02-15 | Glaxo Group Limited | Indole derivatives |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1087629A (zh) | 新的吲哚衍生物 | |
| US6949554B2 (en) | Calcium channel blockers comprising two benzhydril moieties | |
| US6943168B2 (en) | Calcium channel inhibitors comprising benzhydril spaced from piperazine | |
| US6710069B2 (en) | 1-aryl- or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| PT90633B (pt) | Processo para a preparacao de aril- e heteroaril-piperazinilcarboxamidas actuando sobre o sistema nervoso central | |
| US20040259866A1 (en) | Calcium channel blockers comprising two benzhydril moieties | |
| US20040266784A1 (en) | Calcium channel inhibitors comprising benzhydril spaced from piperazine | |
| Matecka et al. | Heteroaromatic analogs of 1-[2-(diphenylmethoxy) ethyl]-and 1-[2-[bis (4-fluorophenyl) methoxy] ethyl]-4-(3-phenylpropyl) piperazines (GBR 12935 and GBR 12909) as high-affinity dopamine reuptake inhibitors | |
| Dutta et al. | Highly selective, novel analogs of 4-[2-(diphenylmethoxy) ethyl]-1-benzylpiperidine for the dopamine transporter: effect of different aromatic substitutions on their affinity and selectivity | |
| Glennon et al. | Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high-affinity. sigma. ligands | |
| JP2009528290A (ja) | 筋肉病の処置のためのｐａｉ−１阻害剤 | |
| DE69921983T2 (de) | Indolderivate als serotonergische mittel | |
| EA011418B1 (ru) | Производные 2-(1h-индолилсульфанил)ариламина для применения при лечении аффективных расстройств, боли, нгдв и стрессового недержания мочи | |
| Choi et al. | Novel 3-aminomethyl-and 4-aminopiperidine analogues of 1-[2-(diphenylmethoxy) ethyl]-4-(3-phenylpropyl) piperazines: Synthesis and evaluation as dopamine transporter ligands | |
| US7541358B2 (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
| DE69903147T2 (de) | Indolylderivate als serotonergische wirkstoffe | |
| AU661190C (en) | Indol derivatives for the treatment of migraine | |
| HK1011680B (en) | Indol derivatives for the treatment of migraine | |
| BRPI0615045A2 (pt) | composto de tiomorfolina e processo para preparação do mesmo | |
| PL162730B1 (pl) | Sposób wytwarzania pochodnych 2-aminobenzimidazolu PL |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C53 | Correction of patent of invention or patent application | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: PATENTEE; FROM: GUBOPULAIFEN CO., LTD. TO: ARLE MIREL - PULLDEASE PHARMACEUTICAL CO., LTD. Free format text: CORRECT: PATENTEE; FROM: HERMILAR LABORATORY CO., LTD. TO: GUBOPULAIFEN CO., LTD. |
|
| CP03 | Change of name, title or address |
Address after: Spain Barcelona Patentee after: ALMIRALL PRODESFARMA, S.A. Patentee before: Valley Populaifen Co.,Ltd. Address after: Spain Barcelona Patentee after: Valley Populaifen Co.,Ltd. Patentee before: Ho M Millar Laboratories Ltd. |
|
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: Spain Barcelona Patentee after: ALMIRALL PRODESFARMA S.A. Address before: Spain Barcelona Patentee before: ALMIRALL PRODESFARMA, S.A. |
|
| C56 | Change in the name or address of the patentee |
Owner name: ALMILAR EXPERIMENTAL ROOM CO., LTD. Free format text: FORMER NAME: ARLE MIREL -PROTEAS PHARMACEUTICAL CO., LTD. |
|
| C56 | Change in the name or address of the patentee |
Owner name: OMIRO CO., LTD. Free format text: FORMER NAME: ALMILAR LABORATORY CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Spain Barcelona Patentee after: ALMIRALL, S.A. Address before: Spain Barcelona Patentee before: ALMIRALL PRODESFARMA S.A. |
|
| C17 | Cessation of patent right | ||
| CX01 | Expiry of patent term |
Expiration termination date: 20130728 Granted publication date: 19970618 |